Current role
Mark Lackner
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Mark Lackner
The proxy statement of Zentalis Pharmaceuticals, Inc. reports total compensation of $1,229,349 for Mark Lackner in fiscal 2025, including a base salary of $153,553. Disclosed compensation is on record for 2 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Zentalis Pharmaceuticals, Inc. (ZNTL)
Proxy statement
CurrentStart not stated–present
-
IDEAYA Biosciences, Inc. (IDYA)
Proxy statement
Start not stated–2020-04-27
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Zentalis Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- Julie Eastland CEO, Board Member
- Kimberly Blackwell, M.D. CEO
- David M. Johnson Chairman
- Scott Myers Chairman, Board Member
- Cam Gallagher CFO
- Vincent Vultaggio CFO, Chief Accounting Officer
- Iris Roth COO
- Iris Roth, Ph.D. COO
- James B. Bucher General Counsel
- David Johnson Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Former Chief Scientific Officer | $153,553 | $1,229,349 |
| 2024 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Former Chief Scientific Officer | $484,397 | $4,788,822 |
Recent activity
No call appearances or filed executive changes recorded yet.